---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-199907"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T18:23:02.383705+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines to acquire EQRx in stock deal valued at ~$1.07B; pipeline updates and FY2023 guidance

## Summary
- Merger consideration: $200M fixed (7.69M shares) plus $870M based on pre-meeting VWAP with 6% discount; expected close Nov 2023.
- Voting agreements secured with >40% of EQRx shares and ~8% of RVMD shares to support the transaction.
- Company confirms FY2023 GAAP net loss guidance of $360M-$400M, inclusive of $40M-$50M stock-based compensation.
- Pipeline updates: RMC-6236 clinical data in NSCLC/pancreatic cancer expected Oct 2023; planning pivotal trials for 2024.
- Post-merger, company will not advance EQRx pipeline; EQRx programs to be wound down and IP returned to partners.

## SEC filing metadata
- accession: 0001193125-23-199907
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/0001193125-23-199907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/d534121d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-199907
- JSON: https://secwatch.observer/filing/0001193125-23-199907.json
- Plain text: https://secwatch.observer/filing/0001193125-23-199907.txt

## Key facts
- Material Agreements
  Revolution Medicines, Inc. entered into Agreement and Plan of Merger with EQRx, Inc. (effective 2023-07-31).
  - Action: entry
  - Agreement: merger
  - Counterparty: EQRx, Inc.
  - Effective: 2023-07-31
  source text: On July 31, 2023, Revolution Medicines, Inc., a Delaware corporation (the “Company”), EQRx, Inc., a Delaware corporation (“EQRx”), Equinox Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Company (“Merger Sub I”), and Equinox Merger Sub II LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of the Company (“Merger Sub II”), entered into an Agreement and Plan of Merger (the “Merger Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/0001193125-23-199907-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.